rewirebio.iobenchmarks
Source

Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141 · Peer-reviewed

DOI: 10.1186/s13059-025-03575-wOriginal source

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)20.7727481294708 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)3Cnet: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)7.053727028 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)3Cnet: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)0 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)3Cnet: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)3.50694444444444 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)3Cnet: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)9.57286560457516 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)3Cnet: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)6.36989208142997 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)3Cnet: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
3Cnet (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)6.64946484588176 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)3Cnet: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)77.4918788366578 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)AlphaMissense: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)90.69319162 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphaMissense: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)65.25670498 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphaMissense: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)92.1365208865208 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphaMissense: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)89.5024970809849 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphaMissense: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)89.2018795078429 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphaMissense: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
AlphaMissense (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)89.4638656922081 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphaMissense: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)25.3406122562259 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)AlphScore: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)33.45524926 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphScore: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)10.95785441 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphScore: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)32.2722878972878 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphScore: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)34.3058374946919 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphScore: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)33.455249258561 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphScore: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
AlphScore (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)34.7025513155192 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)AlphScore: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)71.7872363160532 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)BayesDel_noAF: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)57.10064837 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel_noAF: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)6 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel_noAF: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)56.6324127261627 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel_noAF: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)57.4243527961117 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel_noAF: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)57.1006483695923 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel_noAF: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
BayesDel_noAF (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)58.2494344526282 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel_noAF: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)66.8625108589117 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)BayesDel: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)56.91613959 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)5.444444444 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)56.7713016150516 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)57.0109930077519 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)56.9161395913335 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
BayesDel (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)58.1254265161203 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BayesDel: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)11.2513715328096 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)BLOSUM62: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)14.87319408 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BLOSUM62: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)1.111111111 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BLOSUM62: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)13.7437678062678 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BLOSUM62: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)15.6802443199502 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BLOSUM62: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)14.6755214245133 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BLOSUM62: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
BLOSUM62 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)15.5522147291004 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)BLOSUM62: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
CADD_1.6 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)34.98950589 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.6: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
CADD_1.6 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)1.222222222 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.6: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets
CADD_1.6 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)34.4100401912901 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.6: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only
CADD_1.6 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)35.3831510041601 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.6: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only
CADD_1.6 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)35.0482029805984 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.6: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only
CADD_1.6 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)36.9492893241954 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.6: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled
CADD_1.7 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each)52.0889425921533 percentLivesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins)CADD_1.7: Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense
CADD_1.7 (Livesey and Marsh 2025)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)40.31922489 percentLivesey and Marsh 2025 human DMS benchmark set (36 proteins)CADD_1.7: Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets

Claims

Statements this source supports, each with where in the source it was checked.

Models, benchmarks and other records

Methods (27)

Configurations (99)

Benchmarks (1)

Protocols (6)

Datasets (1)

Evaluations (570)

Use cases (1)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

26 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Artifact SHA-256
1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Doi
10.1186/s13059-025-03575-w
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Licence
CC BY 4.0 (article licence; the workbook carries no separate licence)
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Limitations
4 values
  • All numeric cells use the General number format; values are stored at up to 17 significant digits and printed_value records the shortest round-trip decimal of each stored number.
  • Table S1 has no row 3 and leaves the fitness assay blank for TPK1, SUMO1, UBE2I and CASP7, so the direct and indirect assay groups cannot be counted from it.
  • Table S2 has 93 rows for 97 benchmarked VEPs: BayesDel, EVmutation, PolyPhen-2 and VARITY rows each cover two scored variants.
  • Table S8 prints 'CADD' and 'COSMIS', which have no row in Table S2, and 'CPT' and 'fathmm-XF' where Tables S2 and S3 print 'CPT-1' and 'Fathmm-XF'/'FathmmXF'.
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Media type
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Publication status
peer_reviewed
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Retrieved at
2026-10-14T13:36:25Z
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Review: artifact sha256
1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.review.artifact_sha256

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Review: method note
Re-downloaded from the recorded URL on 2026-10-14 and matched the SHA-256; URL, version, licence and limitations checked.
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.review.method_note

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

Review method
2 values
  • source-hash-verification
  • ai-assisted-source-review
Source metadata
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: 13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
Retrieved: 2026-10-14T13:36:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.review.method

Source artifact SHA-256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70

Hash scope: Hash scope not separately documented; inspect source record

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Excel workbook with the DMS dataset list, VEP list and types, full pairwise win-rate matrices and rank scores for the DMS and clinical benchmarks, bootstrap counts and sensitivity analyses.

1 source record and release history

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: vep-lit-20261014-source-livesey2025-supplementary-2

areas
dna-genomes; proteins-complexes
contexts
research; clinical_research
url
https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-025-03575-w/MediaObjects/13059_2025_3575_MOESM2_ESM.xlsx
version
13059_2025_3575_MOESM2_ESM.xlsx as published with PMC12016141
doi
10.1186/s13059-025-03575-w
retrieved at
2026-10-14T13:36:25Z
artifact sha256
1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70
publication status
peer_reviewed
licence
CC BY 4.0 (article licence; the workbook carries no separate licence)
media type
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
source locator
Sheets 'Legends', 'Table S1' to 'Table S8', 'References'
limitations
All numeric cells use the General number format; values are stored at up to 17 significant digits and printed_value records the shortest round-trip decimal of each stored number.; Table S1 has no row 3 and leaves the fitness assay blank for TPK1, SUMO1, UBE2I and CASP7, so the direct and indirect assay groups cannot be counted from it.; Table S2 has 93 rows for 97 benchmarked VEPs: BayesDel, EVmutation, PolyPhen-2 and VARITY rows each cover two scored variants.; Table S8 prints 'CADD' and 'COSMIS', which have no row in Table S2, and 'CPT' and 'fathmm-XF' where Tables S2 and S3 print 'CPT-1' and 'Fathmm-XF'/'FathmmXF'.
review
reviewer: claude; reviewer note: Claude review agent; no human review claimed. Independent Claude (Opus 5.5) review agent, separate from the extraction agent that built this batch. Automated review only. Transcription, not reproduction.; reviewed at: 2026-10-14T15:30:00Z; artifact sha256: 1b0d792d1a5d3daa95545a7973cabb131c45e42c952e7e5a447a72deef1d1e70; retrieval url: https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-025-03575-w/MediaObjects/13059_2025_3575_MOESM2_ESM.xlsx; method: source-hash-verification; ai-assisted-source-review; method note: Re-downloaded from the recorded URL on 2026-10-14 and matched the SHA-256; URL, version, licence and limitations checked.; note: Hash matches.
Related records

Suggest a correction